|
|
| Orion licenses biomarkers from Johns Hopkins |
| |
Verusmed - Gemini genome has entered the exclusive worldwide agreement with the Johns Hopkins University to commercialize products to identify patients at risk for colorectal cancer.
According to a group of patents and licences issued and owned by the Johns Hopkins waiting for the printing of insulin defects, such as growth factor - 2 (igf2 (genes.
Gemini currently developing blood-based risk assessment tests designed to identify individuals from carrying igf2 biomarker that may be subject to examination and / or any precancerous excess Adenoids, which could be provided to remove colon cancer.
"We believe that our testing and risk assessment and will be easily incorporated into the routine management of colorectal cancer," said Nathan lakey, Orion Executive Officer. "When used in conjunction with colonoscopy screening, and we are testing has the potential to reduce the incidence of colorectal cancer as well as reduce the costs associated with...
|
|
|
|
 |
|
|
| +86-20-87022265-808: الفاكس |
| |
| : ساعات العمل |
| |
| من يوم الاثنين الى السبت من الساعة 8:00 -- 17:30 مساء |
| |
|
|
|
| 
samweb308@hotmail.com
